Deliktaş Onur İlknur, Başoğlu Tuğba, Demircan Nazım Can, Akin Telli Tuğba, Arikan Rukiye, Ercelep Özlem, Turhal Nazım Serdar, Öztürk Mehmet Akif, Yumuk Perran Fulden, Dane Faysal
Division of Oncology, Department of Internal Medicine, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkiye.
Division of Oncology, Department of Internal Medicine, University of Health Sciences, Dr. Lütfi Kırdar Education and Research Hospital, İstanbul, Turkiye.
Turk J Med Sci. 2024 Jul 4;54(6):1205-1214. doi: 10.55730/1300-0144.5901. eCollection 2024.
BACKGROUND/AIM: The Memorial Sloan Kettering Cancer Center (MSKCC) nomogram was developed to predict survivorship in gastric cancer patients undergoing R0 resection. This study aimed to evaluate the predictive power of this nomogram in the Turkish patient population.
Gastric cancer patients over 18 years of age who were admitted to our clinic between 2000 and 2019 and underwent primary curative surgery and R0 resection were included in the study. The 5- and 9-year overall survival (OS) rates of 489 patients were analyzed. Real-life survival rates and those calculated using the MSKCC tool were compared in all the patients and subgroups. The relationship between the variables and survival were analyzed.
The 5-year median observed OS rate for all the patients was 51.7%, while the 5-year median OS rate calculated using the MSKCC tool was 48.5%. The difference between the expected and observed survival rates was 3.2%. The rates were similar and there was no statistically significant difference (p = 0.31). The 9-year median observed OS rate for all the patients was 41.4%, while the 5-year median OS rate calculated using the MSKCC tool was 41%. The difference between the expected and observed survival rates was 0.4%. The rates were similar and there was no statistically significant difference (p = 0.9).
The 5- and 9-year survival rates estimated using the MSKCC tool were correlated with the 5- and 9-year survival rates in the real-life data. Hence, the use of the MSKCC prognostic tool in clinical practice should be expanded.
背景/目的：纪念斯隆凯特琳癌症中心（MSKCC）列线图用于预测接受R0切除的胃癌患者的生存率。本研究旨在评估该列线图在土耳其患者群体中的预测能力。
纳入2000年至2019年间入住我院、年龄超过18岁、接受了原发性根治性手术及R0切除的胃癌患者。分析了489例患者的5年和9年总生存率（OS）。比较了所有患者及其亚组的实际生存率与使用MSKCC工具计算得出的生存率。分析了各变量与生存率之间的关系。
所有患者的5年中位观察OS率为51.7%，而使用MSKCC工具计算得出的5年中位OS率为48.5%。预期生存率与观察生存率之间的差异为3.2%。两者相似，无统计学显著差异（p = 0.31）。所有患者的9年中位观察OS率为41.4%，而使用MSKCC工具计算得出的5年中位OS率为41%。预期生存率与观察生存率之间的差异为0.4%。两者相似，无统计学显著差异（p = 0.9）。
使用MSKCC工具估算的5年和9年生存率与实际数据中的5年和9年生存率相关。因此，应扩大MSKCC预后工具在临床实践中的应用。
